The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab

被引：46

作者：

Di Fabio, Francesca ^{[1
]}

Pinto, Carmine ^{[1
]}

Rojas Llimpe, Fabiola L. ^{[1
]}

Fanti, Stefano ^{[2
]}

Castellucci, Paolo ^{[2
]}

Longobardi, Ciro ^{[1
]}

Mutri, Vita ^{[1
]}

Funaioli, Chiara ^{[1
]}

Sperandi, Francesca ^{[1
]}

Giaquinta, Stefania ^{[1
]}

Martoni, Andrea A. ^{[1
]}

机构：

[1] St Orsola Marcello Malpighi Hosp, Med Oncol Unit, I-40138 Bologna, Italy

[2] St Orsola Marcello Malpighi Hosp, Nucl Med Unit, Bologna, Italy

来源：

GASTRIC CANCER | 2007年 / 10卷 / 04期

关键词：

PET; advanced gastric adenocarcinoma; cetuximab;

D O I：

10.1007/s10120-007-0438-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background. The aim of the study was to evaluate whether the therapy-induced reduction of the F-18-fluorodeoxyglucose positron emission tomography (F-18-FDG-PET) maximum standardized uptake value in patients with advanced gastric adenocarcinoma treated with chemotherapy plus cetuximab could predict the objective response and outcome early during the treatment. Methods. The study was performed as a part of a phase II trial evaluating cetuximab plus the leucovorin/5-fluorouracil/irinotecan (FOLFIRI) regimen. The objective response was evaluated according to the response evaluation criteria in solid tumors (RECIST) every 6 weeks. The early metabolic response evaluated by F-18-FDG-PET was assessed according to our own evaluated cutoff value (< 35%) after receiver operating characteristic (ROC) analysis. Results. Twenty of 22 patients had positive baseline F-18-FDG-PET. The best RECIST response was: complete response (CR), 3; partial response (PR), 9; stable disease (SD), 8. Twelve patients (60%) were classified as metabolic responders and 8 (40%) as nonresponders. At the median follow-up time of 11 months, median time to disease progression (TTP) and overall survival ( OS) for early metabolic responders versus nonresponders were 11 versus 5 months (P = 0.0016) and 16 versus 6 months (P = 0.1493), respectively. Conclusion. The early metabolic response evaluated by F-18-FDGPET predicted the clinical outcome in this series of patients with advanced gastric cancer treated with chemotherapy plus cetuximab.

引用

页码：221 / 227

页数：7

共 27 条

[1]

Role of receptor tyrosine kinases in gastric cancer:: New targets for a selective therapy [J].

Becker, J. C. ;

Mueller-Tidow, C. ;

Serve, H. ;

Domschke, W. ;

Pohle, T. .

WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (21) :3297-3305

[2]

FDG pet studies during treatment:: Prediction of therapy outcome in head and neck squamous cell carcinoma [J].

Brun, E ;

Kjellén, E ;

Tennvall, J ;

Ohlsson, T ;

Sandell, A ;

Perfekt, R ;

Wennerberg, J ;

Strand, SE .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2002, 24 (02) :127-135

[3]

Fanti S, 2005, RADIOL MED, V110, P1

[4]

Survival in stomach cancer is improving -: Results of a nationwide population-based Swedish study [J].

Hansson, LE ;

Sparén, P ;

Nyrén, O .

ANNALS OF SURGERY, 1999, 230 (02) :162-169

[5]

Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world [J].

Kamangar, Farin ;

Dores, Graca M. ;

Anderson, William F. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2137-2150

[6]

NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[7]

Gastric cancer epidemiology and risk factors [J].

Kelley, JR ;

Duggan, JM .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (01) :1-9

[8]

Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer [J].

Kim, SK ;

Kang, KW ;

Lee, JS ;

Kim, HK ;

Chang, HJ ;

Choi, JY ;

Lee, JH ;

Ryu, KW ;

Kim, YW ;

Bae, JM .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (02) :148-155

[9]

Kostakoglu L, 2003, J NUCL MED, V44, P224

[10]

Kostakoglu L, 2004, J NUCL MED, V45, P56

← 1 2 3 →